5-MeO-DMT interactions
Review the current reference classification for 5-MeO-DMT paired with medications or other agents represented in the Arcametric reference library.
Reference information only. This resource summarizes information from external sources and isn't individualized medical advice or a determination of treatment suitability.
Interactors with a reference entry
Cardiovascular
-
5-MeO-DMT and Propranolol Monitor Only
No direct pairing evidence. Theoretical hemodynamic blunting of tachycardia without preventing BP effects. Propranolol label contraindications apply.
Evidence: FDA label (Inderal) + mechanistic
GLP-1/GIP Agonist
-
5-MeO-DMT and Zepbound (tirzepatide) Insufficient Evidence
No plausible pharmacokinetic interaction for inhaled 5-MeO-DMT. No clinically meaningful drug interaction expected beyond background GI or dehydration confounds.
Evidence: FDA label (Zepbound 2025) + mechanistic
SSRI/SNRI
-
5-MeO-DMT and Duloxetine (Cymbalta) Strong Caution
Serotonin syndrome risk (lower than MAOIs) and possible efficacy blunting from serotonin reuptake inhibition. Sparse evidence.
Evidence: Mechanistic theory
-
5-MeO-DMT and Pristiq (desvenlafaxine) Clinician Review
No direct pairing evidence. 5-MeO-DMT with harmala/MAOI exposure is a documented serotonin toxicity risk — MAOI is the critical multiplier. Without MAOI exposure, treat as low-evidence serotonergic combination.
Evidence: Jiang 2015 (harmaline + 5-MeO-DMT case) + FDA label (Pristiq 2017)
Return to the Drug Interaction Checker to look up a specific pair, or open the Knowledge library.